XSHE002433
Market cap28mUSD
Jul 04, Last price
0.27CNY
Name
Guangdong Taiantang Pharmaceutical CoLtd
Chart & Performance
Profile
Guangdong Taiantang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese patent medicines in China. It offers medicines in the forms of creams, ointments, tablets, capsules, pills, and solutions for the areas, including reproductive health, skin health, cardiovascular, cerebrovascular, dermatology, anti-inflammatory, and other areas, as well as acquires, cultivates, processes, and sells Chinese medicinal materials. The company was founded in 1995 and is headquartered in Shantou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 410,361 -43.39% | 724,845 -67.99% | 2,264,175 -36.79% | |||||||
Cost of revenue | 602,880 | 621,251 | 2,171,785 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (192,518) | 103,594 | 92,390 | |||||||
NOPBT Margin | 14.29% | 4.08% | ||||||||
Operating Taxes | 9,316 | 33,259 | ||||||||
Tax Rate | 32.10% | |||||||||
NOPAT | (201,835) | 70,336 | 92,390 | |||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 1,176,972 | 924,307 | 977,457 | |||||||
Long-term debt | 149,621 | 5,027 | 57,391 | |||||||
Deferred revenue | 28,810 | 37,277 | 47,172 | |||||||
Other long-term liabilities | 535,339 | 893,833 | 970,937 | |||||||
Net debt | 901,236 | 470,254 | 521,944 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 222,189 | 833,892 | ||||||||
CAPEX | ||||||||||
Cash from investing activities | 447,406 | 3,136 | 192,538 | |||||||
Cash from financing activities | ||||||||||
FCF | 3,119,709 | 1,025,084 | 430,126 | |||||||
Balance | ||||||||||
Cash | 122,800 | 42,589 | 72,949 | |||||||
Long term investments | 302,558 | 416,491 | 439,956 | |||||||
Excess cash | 404,840 | 422,838 | 399,696 | |||||||
Stockholders' equity | 872,989 | 985,540 | 1,649,715 | |||||||
Invested Capital | 1,806,815 | 5,118,814 | 6,171,162 | |||||||
ROIC | 1.25% | 1.35% | ||||||||
ROCE | 1.87% | 1.41% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 767,391 | 766,773 | 766,773 | |||||||
Price | 2.36 -46.00% | 4.37 -41.42% | 7.46 79.76% | |||||||
Market cap | 1,811,043 -45.95% | 3,350,799 -41.42% | 5,720,128 79.76% | |||||||
EV | 2,814,363 | 3,933,717 | 6,392,801 | |||||||
EBITDA | (85,697) | 231,344 | 223,223 | |||||||
EV/EBITDA | 17.00 | 28.64 | ||||||||
Interest | 195,858 | 105,275 | 153,268 | |||||||
Interest/NOPBT | 101.62% | 165.89% |